Skip to content

Evaluation of N-acetyl cysteine mouth wash as a new treatment approach for gingivitis

Efficacy of N-acetyl cysteine mouth wash in the prevention and treatment of experimental gingivitis: A randomised clinical trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN31352091
Enrollment
60
Registered
2017-02-22
Start date
2017-03-01
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis Oral Health Gingivitis

Interventions

This study has two phases. Participant are randomly divided to three groups by drawing sealed and opaque envelopes containing the codes (A), (B), (C). The induction of experimental gingivitis will be

Sponsors

University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy gingiva with no evidence of periodontitis 2. Male and females aged between 18 to 28 3. Willing to participate and comply with the objectives of the study

Exclusion criteria

Exclusion criteria: 1. Regular users of antiplaque rinses or the use of oral rinses for 30 days before baseline 2. Antibiotics intake within the previous 2 months 3. Smokers 4. Pregnancy or lactation 5. Systemic diseases or long term medications that influencing gingival conditions 6. Orthodontic appliance 7. Presence of detectable increased attachment loss 8. Chewing khat (flowering plant native to the Horn of Africa and the Arabian Peninsula)

Design outcomes

Primary

MeasureTime frame
Bacteria in sub-gingival plaque is measured using bacteria samples from the participants analyzed using DNA sequencing at baseline and day 21 and 35.

Secondary

MeasureTime frame
For the preventative and treatment stages: 1. Plaque is measured using an index scoring system from 0-3 at baseline and at day 7, 14, 21, 28 and 35 2. Gingival index is measured using an index scoring system from 0-3 at baseline and at day 7, 14, 21, 28 and 35 3. Papilla bleeding is measured using an index scoring system from 1-4 at baseline and at day 7, 14, 21, 28 and 35

Countries

Yemen

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026